ARCHIVES

Phase II Study Meets Primary Endpoint, Demonstrating Overall Survival of 5.2 Months

This article is from The Cancer Letter archive.

Vol. 36 No. 9 | September 27, 2013

Download PDF Visit The Full Archive

Related Articles

Letters to the Editor: Love on Mammography; Freireich, Holland On Bernard Fisher

April 15, 1994

CCOP Reponses So Far Indicates application To Total 150-200

August 27, 1982

Blincyto Demonstrates Response In Minimal Residual Disease ALL

December 26, 2014

Cooperative Groups With Cancer Control Contracts Receive Two Year Renewals

March 25, 1983

NI Communications Effort, Saves By Congress, Now A Major National Cancer Program Resource

August 15, 1975

Recurrent Multiple Myeloma Responds To Revimid In Phase II, Side Effects Tolerable

January 31, 2003